DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Apple Restores Telegram to App Store After Content Policy Violation 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Jetstar to Charge for Overhead Cabin Bags From February 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
MENLO PARK, Calif., March 21, 2018 -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the 17th Annual Needham Healthcare Conference in New York at 4:00 p.m. Eastern Time on Tuesday, March 27, 2018.
A live webcast of the presentation will be available through the Investor Relations pages of Geron’s website and at http://wsw.com/webcast/needham86/gern/. Following the live presentation, the webcast will be archived and available for replay at the same address for a period of 30 days.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT:
Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765
[email protected]
[email protected]
